|Dr. Frederick G. Vogt Esq., J.D., Ph.D.||Interim CEO, Pres, Gen. Counsel & Corp. Sec.||752.81k||N/A||1974|
|Mr. Jean-Marc Bellemin M.B.A.||Chief Financial Officer & Principal Accounting Officer||623.6k||N/A||1972|
|Dr. Igor P. Bilinsky||Chief Operating Officer||577.35k||N/A||1973|
|Dr. Friedrich Graf Finckenstein M.D.||Chief Medical Officer||649.13k||N/A||1967|
|Ms. Sara Pellegrino||VP of Investor Relations & PR||N/A||N/A||N/A|
|Ms. Tracy Winton||Sr. VP of HR||N/A||N/A||N/A|
|Mr. Howard B. Johnson M.B.A.||Chief Bus. Officer||N/A||N/A||1960|
|Mr. James Ziegler M.B.A.||Exec. VP of Commercial||N/A||N/A||N/A|
|Mr. Madan Jagasia||Exec. VP of Medical Affairs||N/A||N/A||N/A|
|Dr. Raj K. Puri M.D., Ph.D.||Exec. VP of Regulatory Strategy & Translational Medicine||N/A||N/A||N/A|
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Iovance Biotherapeutics, Inc.’s ISS governance QualityScore as of 1 September 2022 is 8. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 3; Compensation: 9.